Oxford Bio Science Partners (Boston, MA)
Since joining Oxford in 1999, Dr. Fambrough has specialized in financing innovative life science technology companies. His current projects include Dicerna Pharmaceuticals, a second generation RNAi company co-founded by Dr. Fambrough; Ensemble Discovery, which is pioneering DNA-directed synthetic chemistry; Cambrios Technologies, a developer of biologically-inspired electronic materials for the display industry; Xencor, a protein engineering company that engineers antibody Fc regions to enhance potency; and Solstice Neurosciences, a neurology specialty pharmaceutical company. His past investments include RNA interference pioneer Sirna Therapeutics, acquired by Merck for $1.1 billion, and the ultra-high-throughput DNA sequencing equipment company Solexa, acquired by Illumina for $600 million. Prior to Oxford, Dr. Fambrough was a genomic scientist at the Whitehead/MIT Center for Genome Research (now known as the Broad Institute).
Dr. Fambrough graduated from Cornell University and obtained his Ph.D. in genetics from the University of California, Berkeley.
Dicerna Pharmaceuticals, Inc., Ensemble Discovery Corp., Solstice Neurosciences, Inc., Xencor, Inc., Boston Biomedical Research Institute (not-for-profit).